Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice

Florence Joly; Stéphane Oudard; Karim Fizazi; Florence Tubach; Jérémy Jove; Clémentine Lacueille; Stéphanie Lamarque; Estelle Guiard; Aurélie Balestra; Cécile Droz-Perroteau; Annie Fourrier-Reglat; Magali Rouyer; Nicholas Moore

doi:10.1016/j.clgc.2020.02.003

Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice

Florence Joly, Stéphane Oudard, Karim Fizazi, Florence Tubach, Jérémy Jove, Clémentine Lacueille, Stéphanie Lamarque, Estelle Guiard, Aurélie Balestra, Cécile Droz-Perroteau, Annie Fourrier-Reglat, Magali Rouyer, Nicholas Moore

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

11 Citations (Scopus)

Résumé

In a real-life prospective patient outcomes study in 60 patients with metastatic castration-resistant prostate cancer, cabazitaxel in the second line or beyond was associated with stable or improved quality of life, and stable or reduced pain in at least one-third of patients, during and beyond treatment.

langue originale	Anglais
Pages (de - à)	e510-e516
journal	Clinical Genitourinary Cancer
Volume	18
Numéro de publication	5
Les DOIs	https://doi.org/10.1016/j.clgc.2020.02.003
état	Publié - 1 oct. 2020

Accès au document

10.1016/j.clgc.2020.02.003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Joly, F., Oudard, S., Fizazi, K., Tubach, F., Jove, J., Lacueille, C., Lamarque, S., Guiard, E., Balestra, A., Droz-Perroteau, C., Fourrier-Reglat, A., Rouyer, M., & Moore, N. (2020). Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice. Clinical Genitourinary Cancer, 18(5), e510-e516. https://doi.org/10.1016/j.clgc.2020.02.003

@article{0592b65117c34cc194321de7d943c3b1,

title = "Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice",

abstract = "In a real-life prospective patient outcomes study in 60 patients with metastatic castration-resistant prostate cancer, cabazitaxel in the second line or beyond was associated with stable or improved quality of life, and stable or reduced pain in at least one-third of patients, during and beyond treatment.",

keywords = "FACT-P scores, Pain score BPI-S, Prospective observational study, Real-world information, Survival",

author = "Florence Joly and St{\'e}phane Oudard and Karim Fizazi and Florence Tubach and J{\'e}r{\'e}my Jove and Cl{\'e}mentine Lacueille and St{\'e}phanie Lamarque and Estelle Guiard and Aur{\'e}lie Balestra and C{\'e}cile Droz-Perroteau and Annie Fourrier-Reglat and Magali Rouyer and Nicholas Moore",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = oct,

day = "1",

doi = "10.1016/j.clgc.2020.02.003",

language = "English",

volume = "18",

pages = "e510--e516",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

number = "5",

}

Joly, F, Oudard, S, Fizazi, K, Tubach, F, Jove, J, Lacueille, C, Lamarque, S, Guiard, E, Balestra, A, Droz-Perroteau, C, Fourrier-Reglat, A, Rouyer, M & Moore, N 2020, 'Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice', Clinical Genitourinary Cancer, VOL. 18, Numéro 5, p. e510-e516. https://doi.org/10.1016/j.clgc.2020.02.003

TY - JOUR

T1 - Quality of Life and Pain During Treatment of Metastatic Castration-resistant Prostate Cancer With Cabazitaxel In Routine Clinical Practice

AU - Joly, Florence

AU - Oudard, Stéphane

AU - Fizazi, Karim

AU - Tubach, Florence

AU - Jove, Jérémy

AU - Lacueille, Clémentine

AU - Lamarque, Stéphanie

AU - Guiard, Estelle

AU - Balestra, Aurélie

AU - Droz-Perroteau, Cécile

AU - Fourrier-Reglat, Annie

AU - Rouyer, Magali

AU - Moore, Nicholas

PY - 2020/10/1

Y1 - 2020/10/1

N2 - In a real-life prospective patient outcomes study in 60 patients with metastatic castration-resistant prostate cancer, cabazitaxel in the second line or beyond was associated with stable or improved quality of life, and stable or reduced pain in at least one-third of patients, during and beyond treatment.

AB - In a real-life prospective patient outcomes study in 60 patients with metastatic castration-resistant prostate cancer, cabazitaxel in the second line or beyond was associated with stable or improved quality of life, and stable or reduced pain in at least one-third of patients, during and beyond treatment.

KW - FACT-P scores

KW - Pain score BPI-S

KW - Prospective observational study

KW - Real-world information

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85082507432&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2020.02.003

DO - 10.1016/j.clgc.2020.02.003

M3 - Article

C2 - 32229267

AN - SCOPUS:85082507432

SN - 1558-7673

VL - 18

SP - e510-e516

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 5

ER -